Scarica l'app Stockscreener
83.50
0.04%
-0.035
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRNX Giù?
Forum
Previsione
Crinetics Pharmaceuticals Inc Borsa (CRNX) Ultime notizie
Stifel cuts Crinetics stock rating to hold on Vertex acquisition - Investing.com
Vertex’s Crinetics Deal Balances Growth with Integration Risk - MarketBeat
Morgan Stanley Analyzes Vertex Pharmaceuticals' (VRTX.US) $10 Billion Acquisition of Crinetics: Completing Its Endocrinology Pipeline and Unlocking Growth Potential with Two Core Drugs - 富途牛牛
Vertex Pharmaceuticals (VRTX) Buys Crinetics, Where Does Fair Value Sit Now? - Yahoo! Finance Canada
Vertex to acquire Crinetics in deal worth around $10.0bn - PMLiVE
Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil - BioSpace
Viking Therapeutics (VKTX) Draws Takeover Focus After Vertex's $10 Billion Crinetics Deal - Yahoo Finance
Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It. - The Motley Fool
Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It. - The Motley Fool
Strength Seen in CRINETICS PHARM (CRNX): Can Its 98.7% Jump Turn into More Strength? - Yahoo Finance
The $10B Integration Problem Vertex Hasn’t Solved Yet - The Clinical Trial Vanguard
Narrow-Moat Vertex's Strong CF Cash Flows Support Expansion Into Endocrinology Via Crinetics - Morningstar
Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know. - The Motley Fool
Why Did CRNX, D, BCRX Stocks Surge To 52-Week Highs Today? - Yahoo Finance
Why Crinetics Stock Doubled After Vertex’s $10 Billion Buyout - BeInCrypto
Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals in $10 Billion All-Cash Deal - Global Legal Chronicle
Vertex to acquire Crinetics in $10 billion rare-disease push - MSN
Investigation launched into Crinetics Pharma bo... - Pluang
Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms - The Boston Globe
Crinetics Pharmaceuticals director sells $120,000 in stock - Investing.com
Vertex Pharma’s Growth Strategy Leads to Its Biggest-Ever M&A Deal - MedCity News
Form 4 Crinetics Pharmaceuticals Inc For: 7 July By Investing.com - Investing.com India
Vertex Eyes Expansion Beyond Cystic Fibrosis with Planned $10B Crinetics Buyout - Genetic Engineering and Biotechnology News
Crinetics Pharmaceuticals director sells $120,000 in stock By Investing.com - Investing.com Canada
Crinetics (CRNX) director sells 3,000 shares at $40 in planned trade - Stock Titan
Vertex (VRTX) Is Buying Crinetics For $10 Billion And Entering Endocrinology - Yahoo Finance
Eli Lilly price target boost, Vertex-Crinetics deal, Meta's new social media lawsuit - Yahoo Finance
The Changing Reality of Pharmaceutical Commercialization | PharmExec - Pharmaceutical Executive
Vertex to buy Crinetics in an all-cash deal valued at $10 billion - CNBC
Vertex Pays $10 Billion to Enter Rare Endocrine Disease - TradingView
Vertex's $10B Crinetics deal marks its clearest step yet toward biopharma's top ranks - Endpoints News
This Biotech Stock Is Soaring 99% After Vertex Agrees to Takeover Deal - Barron's
Vertex to Acquire Crinetics Pharmaceuticals for $10 Billion - Pharmaceutical Executive
CRNX Soars On $10B Vertex Buyout As Trading Dynamics Shift - StocksToTrade
CRNX Downgraded by Jones Trading -- Rating Changed to Hold - GuruFocus
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Crinetics Pharmaceuticals Cut to Hold From Buy by Jones Trading - Moomoo
Crinetics Pharmaceuticals (CRNX) Agreed To A $10 Billion All Cash Sale To Vertex - simplywall.st
CRNX Soars On Vertex’s $10B Buyout And Tight Trading Range - StocksToTrade
Endocrinology becomes Vertex’s fifth pillar with $10B Crinetics buy - BioWorld News
SpaceX Joins Nasdaq 100; Crinetics Pharmaceuticals Soars on Buyout | Stock Movers - marketscreener.com
Compass says depression drug has long-lasting benefits - STAT
Crinetics (CRNX) Soars 98.8% to Reach $83.55 - GuruFocus
CRNX Downgraded by Oppenheimer -- Rating Changed to Perform - GuruFocus
Vertex Pharmaceuticals (VRTX) Announces Strategic Merger with Cr - GuruFocus
Vertex makes largest ever acquisition with $10bn Crinetics deal - BioXconomy
Crinetics Pharmaceuticals stock hits all-time high at 83.59 USD By Investing.com - Investing.com Nigeria
Jones Trading downgrades Crinetics stock rating on Vertex acquisition - Investing.com
Crinetics Pharmaceuticals stock hits all-time high at 83.59 USD - Investing.com
Vertex Pharmaceuticals to acquire Crinetics in a $10 billion deal, sending the latter's share price nearly doubling - 富途牛牛
Crinetics shares surge after Vertex agrees to $10B cash buyout - Invezz
Crinetics Pharmaceuticals Stock (CRNX) Opinions on Vertex Acquisition - Quiver Quantitative
CRNX Stock Soars On $10B Vertex Takeover Deal - StocksToTrade
Crinetics Acquisition Creates A ‘Fifth Commercial Pillar’ For Vertex, Says Analyst – Why HC Wainwright Sees A 24% Upside Potential In VRTX Stock - Yahoo Finance
Vertex Pharmaceuticals buying Crinetics for $10 billion - qz.com
CRINETICS PHARMACEUTICALS, INC. (CRNX) - MSN
Crinetics (CRNX) Stock Surges Ahead of Vertex's $10 Billion Acqu - GuruFocus
Dow Gains Over 200 Points; US Trade Deficit Widens In MayCrinetics Pharmaceuticals (NASDAQ:CRNX), Digi - Benzinga
Crinetics stocks surge after Vertex agrees to $10B cash buyout - Invezz
Cantor Sees 'Clear Strategic Rationale' Behind Vertex's Buy of Crinetics -- Market Talk - Moomoo
Vertex Doesn't Need Crinetics Deal to Generate $5 Billion to Be Success, Evercore Says -- Market Talk - Moomoo
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Crinetics Pharmaceuticals, Inc. (CRNX) - TMX Newsfile
VRTX to Strengthen Rare Disease Portfolio With $10B Crinetics Buyout - Yahoo Finance
Crinetics Pharmaceuticals Acquired by Fortress Biotech for $10 B - GuruFocus
Pharmalittle: We’re reading about a $10 billion Vertex deal, the pace of FDA drug approvals, and more - STAT
2.09%
6.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):